Literature DB >> 30231231

Atezolizumab Treatment of Nonsquamous NSCLC.

Martin Reck1, Robert M Jotte2, Mark A Socinski3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30231231     DOI： 10.1056/NEJMc1809195

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.

Authors:  Giampaolo Tortora; Emilio Bria; Vincenzo Di Noia; Ettore D'Argento; Sara Pilotto; Emanuele Vita; Miriam Grazia Ferrara; Paola Damiano; Marta Ribelli; Antonella Cannella; Antonella Virtuoso; Andrea Fattorossi; Giovanni Luca Ceresoli; Michele Milella; Giordano Domenico Beretta
Journal:  Cancer Immunol Immunother       Date:  2020-11-24       Impact factor: 6.968

2.  Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Authors:  Gisela María Suárez; Mauricio Catalá; Yadira Peña; Susana Portela; Ana Laura Añé-Kourí; Amnely González; Patricia Lorenzo-Luaces; Manuel Díaz; María de Los A Molina; Karla Pereira; Jenysbel de la C Hernández; Raúl Ramos; Mary Carmen Reyes; Nuris Ledón; Zaima Mazorra; Tania Crombet; Agustin Lage; Danay Saavedra
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

Review 3.  The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer.

Authors:  Tania Crombet Ramos; Orestes Santos Morales; Grace K Dy; Kalet León Monzón; Agustín Lage Dávila
Journal:  Front Oncol       Date:  2021-06-15       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.